Literature DB >> 9121223

Effects of defibrotide on leukocyte-endothelial cell interaction in the rat mesenteric vascular bed: role of P-selectin.

R Scalia1, L Kochilas, B Campbell, A M Lefer.   

Abstract

The effects of defibrotide on leukocyte-endothelial cell interaction and P-selectin surface expression on the microvascular endothelium were investigated. Intravital microscopy was performed in the rat mesenteric microcirculation. The rat mesentery was superfused either with Krebs-Henseleit solution (i.e., control) or 50 microM NG nitro-L-arginine methyl ester (L-NAME). Defibrotide (40 mg/kg) was intravenously infused to control rats and to L-NAME superfused rats. P-selectin expression on mesenteric venules was also investigated by immunohistochemistry. L-NAME caused a significant, time-dependent increase in leukocyte rolling (13 +/- 5 to 101 +/- 18 cells/ min; p < 0.001) and adherence (1.6 +/- 0.7 to 12 +/- 2.5 cells/100 microns length of venule; p < 0.01) compared to control superfused rats. However, intravenous infusion of defibrotide (40 mg/kg) consistently decreased the L-NAME-induced leukocyte rolling (101 +/- 18 to 9.3 +/- 1.3 cells/min; p < 0.001) and adherence (12 +/- 2.5 to 1.9 +/- 1.1 cells/100 microns length of venule; p < 0.01). Exposure of rat mesentery to L-NAME consistently increased P-selectin surface expression (p < 0.01) on the vascular endothelium which was significantly attenuated by defibrotide (p < 0.05). In vivo administration of defibrotide can reduce leukocyte rolling and adherence in the mesenteric rat microvasculature by attenuating P-selectin expression. Since P-selectin was upregulated by the specific nitric oxide synthase inhibitor L-NAME, the present study also confirms the crucial role exerted by nitric oxide in attenuating leukocyte-endothelial cell interaction during various pathophysiological conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9121223

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  10 in total

Review 1.  Concise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilization.

Authors:  Jonathan Hoggatt; Jennifer M Speth; Louis M Pelus
Journal:  Stem Cells       Date:  2013-12       Impact factor: 6.277

Review 2.  The use of defibrotide in blood and marrow transplantation.

Authors:  Paul G Richardson; Enric Carreras; Massimo Iacobelli; Bijan Nejadnik
Journal:  Blood Adv       Date:  2018-06-26

3.  Defibrotide: a Swiss Army knife intervention in the battle against cerebral malaria.

Authors:  Julie M Moore; John W Avery
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03       Impact factor: 8.311

4.  Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria.

Authors:  Ivo M B Francischetti; Carlo J Oliveira; Graciela R Ostera; Stephanie B Yager; Françoise Debierre-Grockiego; Vanessa Carregaro; Giovanna Jaramillo-Gutierrez; Jen C C Hume; Lubin Jiang; Samuel E Moretz; Christina K Lin; José M C Ribeiro; Carole A Long; Brandi K Vickers; Ralph T Schwarz; Karl B Seydel; Massimo Iacobelli; Hans C Ackerman; Prakash Srinivasan; Regis B Gomes; Xunde Wang; Robson Q Monteiro; Michail Kotsyfakis; Anderson Sá-Nunes; Michael Waisberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-23       Impact factor: 8.311

Review 5.  Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.

Authors:  Gillian M Keating
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859

6.  Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.

Authors:  Constantine S Mitsiades; Cecile Rouleau; Cinara Echart; Krishna Menon; Beverly Teicher; Maria Distaso; Antonio Palumbo; Mario Boccadoro; Kenneth C Anderson; Massimo Iacobelli; Paul G Richardson
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

Review 7.  Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy.

Authors:  Qian Zhou; James K Liao
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 8.  Mobilized peripheral blood: an updated perspective.

Authors:  Darja Karpova; Michael P Rettig; John F DiPersio
Journal:  F1000Res       Date:  2019-12-20

9.  COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies.

Authors:  Eleonora Calabretta; Jose M Moraleda; Massimo Iacobelli; Ruben Jara; Israel Vlodavsky; Peter O'Gorman; Antonio Pagliuca; Clifton Mo; Rebecca M Baron; Alessio Aghemo; Robert Soiffer; Jawed Fareed; Carmelo Carlo-Stella; Paul Richardson
Journal:  Br J Haematol       Date:  2021-02-04       Impact factor: 6.998

10.  Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease.

Authors:  David García-Bernal; Marta Palomo; Carlos M Martínez; José E Millán-Rivero; Ana I García-Guillén; Miguel Blanquer; Maribel Díaz-Ricart; Robert Sackstein; Enric Carreras; Jose M Moraleda
Journal:  J Cell Mol Med       Date:  2020-06-10       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.